---
$id: https://graph.org.ai/products/commodity/51111820
$type: Product
source: UNSPSC
code: "51111820"
title: "Letrozole"
class: "51111800"
classTitle: "Hormones and antihormones"
family: "51110000"
familyTitle: "Antineoplastic agents"
segment: "51000000"
segmentTitle: "Pharmaceutical Products incl. Contraceptives and Vaccines"


---

# Letrozole

**UNSPSC Code**: 51111820
**Class**: [Hormones and antihormones](Hormones and antihormones.mdx)
**Family**: [Antineoplastic agents](../Antineoplastic agents.mdx)
**Segment**: [Pharmaceutical Products incl. Contraceptives and Vaccines](../../Pharmaceutical Products incl. Contraceptives and Vaccines.mdx)

This classification denotes a non-steroidal aromatase inhibitor with the molecular formula C17H11N5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7LKK855W8I, chemically known as 4,4-(1h-1,2,4-triazol-1-ylmethylene)dibenzonitrile but generally known as letrozole, which bears US NIH Compound Identifier 3902. European Medicines Agency schedules Letrozole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08444MIG. The term LETROZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 8 No. 3 1994, List 34). World Health Organization schedules letrozole in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule letrozole under HS 29339990 and SITC 51577. As of Q4 2014, LETROZOLE remains the US FDA Preferred Term for this commodity. Letrozole bears US NLM identifiers UMLS ID C0246421 and NCI Concept Code C1527. SMILES: N1(NCNC1)C(C1CCC(CC1)C#N)C1CCC(CC1)C#N.

